NP方案二线化疗对25例晚期非小细胞肺癌的疗效

Navelbine Combined with Cisplatin as Second-Line Treatment in 25 Patients with Advanced Non-Small Cell Lung Cancer

目的 探索二线化疗方案对晚期非小细胞肺癌 (NSCLC )的疗效和不良反应。方法 采用NP方案即进口长春瑞宾(NVB) 2 5mg/m2 ,iv ,第 1,8天 ;顺铂 (DDP) 80mg/m2 ,iv ,第 1天 ;作为二线方案治疗经病理和 (或 )细胞学诊断的 2 5例晚期NSCLC。 2 2例曾用含铂类方案化疗 ,经用 1个化疗方案治疗后复发或进展。结果 可评价疗效的 2 5例中 ,无CR(完全缓解 ) ,PR(部分缓解 ) 3例 ,SD(稳定 ) 14例 ,PD (进展 ) 8例 ,有效率 12 % ;中位生存期 9个月 ;1年生存率 3 6%。 3例获PR者病理诊断均为腺癌 ,治疗后生存期分别为 7个月、16个月和 16个月。化疗的不良反应主要是血液学毒性 ,但患者可以耐受。结论 NVB联合DDP用于二线化疗方案治疗晚期NSCLC临床有效 ,患者耐受性尚可 。

Objective To evaluate the effectiveness and safety of the second-line treatment in patients with advanced non-small cell lung cancer(NSCLC).Methods 25 patients with histologically and/or Cytologically confirmed advanced NSCLC were treated with navelbine(NVB) 25 mg/m 2 on d1,8 and cisplatin(DDP) 80 mg/m 2 on d1 every 3 weeks.22 patients had received prior platinum-containing chemotherapy.All patients had relapsed after receiving one prior chemotherapy regimen.Results 3 of 25 assessable patients achieved partial response(PR),17 had stable disease(SD),5 had progressive disease(PD),there was no complete response(CR).The response rate was 12% and the median survival of all patients was 9 months.One-year survival rate was 36%.3 patients with partial response were diagnosed as adenocarcinoma by histology.The survival time of the 3 patients was 7 months,16 months and 16 months respectively.Hematologic toxicity was the main side effect in this trial,and they were well tolerated.Conclusion NVB combined with DDP is an effective regimen with tolerable toxicity in the second-line treatment of NSCLC.The randomized trial should be carried out in the future.